nach oben

CardioVascular and Interventional Radiology

Erschienen in:

16.12.2016 | CIRSE Standards of Practice Guidelines

CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma

verfasst von: Miltiadis E. Krokidis, Franco Orsi, Konstantinos Katsanos, Thomas Helmberger, Andy Adam

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

Renal cell carcinoma (RCC) comprises approximately 3.8% of all new cancers in the western world; the detection rate of RCC has been increasing in the past 10 years by approximately 1.7% per year [1]. This rise is attributed to the increased number of diagnostic cross-sectional scans in which asymptomatic renal tumours are incidentally detected. The median age at diagnosis is 64 years [2]. …

http://seer.cancer.gov/statfacts/html/kidrp.html. Accessed Nov 2015.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRef

Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM. Hereditary renal cancers. Radiology. 2003;226:33–46.PubMedCrossRef

DeVita Jr VT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biological complexity. Eur Urol. 2015;67:85–97.PubMedCrossRef

Bex A. Classification of renal cell carcinoma subtypes: there is more than meets the eye. Eur Urol. 2015;67:98–9.PubMedCrossRef

Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.PubMedCrossRef

Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press; 2004. p. 7.

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37:1469–89.PubMedCrossRef

10.

Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics. 2008;28(5):1325–38.PubMedCrossRef

11.

Zagoria RJ, Dyer RB, Wolfman NT, Hinn GC, Chen YM. Radiology in the diagnosis and staging of renal cell carcinoma. Crit Rev Diagn Imaging. 1990;31(1):81–115.PubMed

12.

Choudhary S, Rajesh A, Mayer NJ, Mulcahy KA, Haroon A. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clin Radiol. 2009;64(5):517–22.PubMedCrossRef

13.

Millet I, Doyon FC, Hoa D, Thuret R, Merigeaud S, Serre I, et al. Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT? AJR. 2011;197:887–96.PubMedCrossRef

14.

Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR Am J Roentgenol. 2010;195(6):W421–7.PubMedCrossRef

15.

Hindman N, Ngo L, Genega EM, Melamed J, Wei J, Braza JM, et al. Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology. 2012;265(2):468–77.PubMedPubMedCentralCrossRef

16.

Pedrosa I, Sun MR, Spencer M, Genega EM, Olumi AF, Dewolf WC, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008;28(4):985–1003.PubMedCrossRef

17.

Putra LG, Minor TX, Bolton DM, Appu S, Dowling CR, Neerhut GJ. Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. Urology. 2009;74(3):535–9.PubMedCrossRef

18.

Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, et al. Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. Radiology. 2012;265(3):799–808.PubMedPubMedCentralCrossRef

19.

Capitanio U, Montorsi F. Renal cancer. Lancet. 2015. (epub ahead of print).

20.

NCCN guidelines: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#kidney. Accessed Nov 2015.

21.

Maxwell NJ, Saleem AN, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolisation in the palliative treatment of renal carcinoma. Br J Radiol. 2007;80(950):96–102.PubMedCrossRef

22.

Guy L, Alfidja AT, Chabrot P, Ravel A, Boiteux JP, Boyer L. Palliative transarterial embolization of renal tumors in 20 patients. Int Urol Nephrol. 2007;39(1):47–50.PubMedCrossRef

23.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef

24.

McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59:816–20.PubMedCrossRef

25.

Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy vs. radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181(1):55–61.PubMedCrossRef

26.

Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer. 2009;115(7):1465–71.PubMedCrossRef

27.

Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008;179(2):468–71.PubMedCrossRef

28.

Patard JJ, Bensalah KC, Pantuck AJ, Klatte T, Crepel M, Verhoest G, et al. Radical nephrectomy is not superior to nephron sparing surgery in PT1B-PT2N0M0 renal tumours: A matched comparison analysis in 546 cases. Eur Urol Suppl. 2008;7(3):194.CrossRef

29.

Kutikov A, Uzzo RG. The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.PubMedCrossRef

30.

Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009;56(5):786–93.PubMedCrossRef

31.

Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. J Urol. 2010;183(5):1708–13.PubMedCrossRef

32.

Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.PubMedCrossRef

33.

Rais-Bahrami S, Guzzo TJ, Jarrett TW, Kavoussi LR, Allaf ME. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int. 2009;103:1355–8.PubMedCrossRef

34.

Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197:589–97.PubMedCrossRef

35.

Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8:473–7.PubMedCrossRef

36.

Guðmundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B, Swedish Kidney Cancer Quality Register Group. Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol. 2011;60(5):975–82.PubMedCrossRef

37.

McGovern FJ, Wood BJ, Goldberg SN, Mueller PR. Radiofrequency ablation of renal cell carcinoma via image guided needle electrodes. J Urol. 1999;161(2):599–600.PubMedCrossRef

38.

Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. Part 1. Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR. 2005;185:64–71.PubMedCrossRef

39.

Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, et al. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR. 2004;183:201–7.PubMedCrossRef

40.

Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37(6):1494–9.CrossRef

41.

Breen D, Bryant TJ, Abbas A, Shepherd B, McGill N, Anderson JA, et al. Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int. 2013;112(6):758–65.PubMedCrossRef

42.

Schmit GD, Schenck LA, Thompson RH, Boorjian SA, Kurup AN, Weisbrod AJ, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology. 2014;272(3):903–10.PubMedCrossRef

43.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.PubMedCrossRef

44.

Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):49–56.CrossRef

45.

Georgiades C, Rodriguez R. Renal tumor ablation. Tech Vasc Interv Radiol. 2013;16(4):230–8.PubMedCrossRef

46.

Schmit GD, Kurup AN, Weisbrod AJ, Thompson RH, Boorjian SA, Wass CT, et al. ABLATE: a renal ablation planning algorithm. AJR Am J Roentgenol. 2014;202(4):894–903.PubMedCrossRef

47.

Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter J, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology. 1988;169(2):363–5.PubMedCrossRef

48.

Paudice N, Zanazzi M, Agostini S, Bertelli E, Caroti L, Carta P, et al. Contrast-enhanced ultrasound assessment of complex cystic lesions in renal transplant recipients with acquired cystic kidney disease: preliminary experience. Transplant Proc. 2012;44(7):1928–9.PubMedCrossRef

49.

Sahni VA, Silverman G. Imaging management of incidentally detected small renal masses. Semin Interv Radiol. 2014;31:9–19.CrossRef

50.

Grobner T. Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104–8.PubMedCrossRef

51.

http://www.esur.org/guidelines/. Accessed Nov 2015.

52.

Tsiviam M, Rampersaud Jr EN, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, et al. Small renal mass biopsy–how, what and when: report from an international consensus panel. BJU Int. 2014;113(6):854–63.CrossRef

53.

Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, et al. Comparison of accuracy of 14-, 18- and 20-G needles in ex vivo renal mass biopsy: a prospective, blinded study. BJU Int. 2010;105(7):940–5.PubMedCrossRef

54.

Veltri A, Garetto I, Tosetti I, Busso M, Volpe A, Pacchioni D, et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol. 2011;21(2):393–401.PubMedCrossRef

55.

Uppot RN, Silverman SG, Zagoria RJ, Tuncali K, Childs DD, Gervais DA. Imaging-guided percutaneous ablation of renal cell carcinoma: a primer of how we do it. AJR Am J Roentgenol. 2009;192(6):1558–70.PubMedCrossRef

56.

Breen DJ, Railton NJ. Minimally invasive treatment of small renal tumors: trends in renal cancer diagnosis and management. Cardiovasc Interv Radiol. 2010;33(5):896–908.CrossRef

57.

Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36.PubMedCrossRef

58.

Goldberg SN, Gazelle GS. Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology. 2001;48:359–67.PubMed

59.

Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60(2 Suppl 1):40–9.PubMedCrossRef

60.

Veltri A, De Fazio G, Malfitana V, Isolato G, Fontana D, Tizzani A, et al. Percutaneous US-guided RF thermal ablation for malignant renal tumors: preliminary results in 13 patients. Eur Radiol. 2004;14:2303–10.PubMedCrossRef

61.

Georgiades C, Rodriguez R, Azene E, Weiss C, Chaux A, Gonzalez-Roibon N, et al. Determination of the nonlethal margin inside the visible “ice-ball” during percutaneous cryoablation of renal tissue. Cardiovasc Interv Radiol. 2013;36(3):783–90.CrossRef

62.

Weld KJ, Hruby G, Humphrey PA, Ames CD, Landman J. Precise characterization of renal parenchymal response to single and multiple cryoablation probes. J Urol. 2006;176(2):784–6.PubMedCrossRef

63.

Campbell SC, Krishnamurthi V, Chow G, Hale J, Myles J, Novick AC. Renal cryosurgery: experimental evaluations of treatment parameters. Urology. 1998;52(1):29–34.PubMedCrossRef

64.

Lubner MG, Brace CL, Ziemlewicz TJ, Hinshaw JL, Lee Jr FT. Microwave ablation of hepatic malignancy. Semin Interv Radiol. 2013;30(1):56–66.CrossRef

65.

Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology. 2007;72(Suppl 1):124–31.PubMedCrossRef

66.

Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–9.PubMedCrossRef

67.

Knavel EM, Hinshaw JL, Lubner MG, Andreano A, Warner TF, Lee Jr FT, et al. High-powered gas-cooled microwave ablation: shaft cooling creates an effective stick function without altering the ablation zone. AJR Am J Roentgenol. 2012;198:W260–5.PubMedPubMedCentralCrossRef

68.

Cheng Z, Xiao Q, Wang Y, Sun Y, Lu T, Liang P. 915 MHz microwave ablation with implanted internal cooled-shaft antenna: initial experimental study in in vivo porcine livers. Eur J Radiol. 2011;79:131–5.PubMedCrossRef

69.

Horn JC, Patel RS, Kim E, Nowakowski FS, Lookstein RA, Fischman AM. Percutaneous microwave ablation of renal tumors using a gas-cooled 2.4-GHz probe: technique and initial results. J Vasc Interv Radiol. 2014;25(3):448–53.PubMedCrossRef

70.

Wah TM, Irving HC. Infectious complications after percutaneous radiofrequency ablation of renal cell carcinoma in patients with ileal conduit. J Vasc Interv Radiol. 2008;19(9):1382–5.PubMedCrossRef

71.

Fotiadis NI, Sabharwal T, Morales JP, Hodgson DJ, O’Brien TS, Adam A. Combined percutaneous radiofrequency ablation and ethanol injection of renal tumours: midterm results. Eur Urol. 2007;52(3):777–84.PubMedCrossRef

72.

Krokidis M, Spiliopoulos S, Jarzabek M, Fotiadis N, Sabharwal T, O’Brien T, et al. Percutaneous radiofrequency ablation of small renal tumours in patients with a single functioning kidney: long-term results. Eur Radiol. 2013;23(7):1933–9.PubMedCrossRef

73.

Boss A, Clasen S, Kuczyk M, Anastasiadis A, Schmidt D, Graf H, et al. Magnetic resonance-guided percutaneous radiofrequency ablation of renal cell carcinomas: a pilot clinical study. Invest Radiol. 2005;40:583–90.PubMedCrossRef

74.

Gupta A, Allaf ME, Kavoussi LR, Jarrett TW, Chan DY, Su LM, et al. Computerized tomography guided percutaneous renal cryoablation with the patient under conscious sedation: initial clinical experience. J Urol. 2006;175:447–52.PubMedCrossRef

75.

Miki K, Shimomura T, Yamada H, Kishimoto K, Ohishi Y, Harada J, et al. Percutaneous cryoablation of renal cell carcinoma guided by horizontal open magnetic resonance imaging. Int J Urol. 2006;13:880–4.PubMedCrossRef

76.

Park BK, Kim SH, Byun JY, Kim YS, Kwon GY, Jang IS. CT-guided instillation of 5% dextrose in water into the anterior pararenal space before renal radiofrequency ablation in a porcine model: positive and negative effects. J Vasc Interv Radiol. 2007;18:1561–9.PubMedCrossRef

77.

Kam AW, Littrup PJ, Walther MM, Hvizda J, Wood BJ. Thermal protection during percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol. 2004;15(7):753–8.PubMedPubMedCentralCrossRef

78.

Wah TM, Koenig P, Irving HC, Gervais DA, Mueller PR. Radiofrequency ablation of a central renal tumour: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol. 2005;16(11):1551–5.PubMedCrossRef

79.

Cantwell CP, Wah TM, Gervais DA, Eisner BH, Arellano R, Uppot RN, et al. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water. J Vasc Interv Radiol. 2008;19(7):1034–40.PubMedCrossRef

80.

Tacke J, Mahnken A, Bucker A, Rohde D, Gunther RW. Nephron-sparing percutaneous ablation of a 5 cm renal cell carcinoma by superselective embolization and percutaneous RF-ablation. Rofo. 2001;173:980–3.PubMedCrossRef

81.

Tacke J, Mahnken AH, Gunther RW. Percutaneous thermal ablation of renal neoplasms. Rofo. 2005;177:1631–40.PubMedCrossRef

82.

Mahnken AH, Penzkofer T, Bruners P, Günther RW, Brehmer B. Interventional management of a renal cell carcinoma by radiofrequency ablation with tagging and cooling. Korean J Radiol. 2009;10(5):523–6.PubMedPubMedCentralCrossRef

83.

Meloni MF, Bertolotto M, Alberzoni C, Lazzaroni S, Filice C, Livraghi T, et al. Follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: contrast-enhanced sonography versus contrast-enhanced CT or MRI. AJR Am J Roentgenol. 2008;191(4):1233–8.PubMedCrossRef

84.

Rutherford EE, Cast JE, Breen DJ. Immediate and long-term CT appearances following radiofrequency ablation of renal tumours. Clin Radiol. 2008;63(2):220–30.PubMedCrossRef

85.

Smith S, Gillams A. Imaging appearances following thermal ablation. Clin Radiol. 2008;63:1–11.PubMedCrossRef

86.

Merkle EM, Nour SG, Lewin JS. MR imaging follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: findings in 18 patients during first 6 months. Radiology. 2005;235:1065–71.PubMedCrossRef

87.

Philllips B, Ball C, Sacket D, Badenoch D, Straus S, Haynes B, et al. Oxford Centre for Evidence-Based Medicine-Levels of Evidence (2009). Centre for Evidence-Based Medicine. www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009. Accessed Nov 2015.

88.

Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol. 2013;63(3):486–92.PubMedCrossRef

89.

Lane BR, Campbell SC, Gill IS. 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol. 2013;190(1):44–9.PubMedCrossRef

90.

Katsanos K, Mailli L, Krokidis M, McGrath A, Sabharwal T, Adam A. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Interv Radiol. 2014;37(2):427–37.CrossRef

91.

Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol. 2010;28(6):460–8.PubMedCrossRef

92.

Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67(2):252–9.PubMedCrossRef

93.

Ma Y, Bedir S, Cadeddu JA, Gahan JC. Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int. 2014;113:51–5.PubMedCrossRef

94.

Breen DJ, Rutherford EE, Stedman B, Roy-Choudhury SH, Cast JEI, Hayes MC, et al. Management of renal tumors by image-guided radiofrequency ablation: experience in 105 tumors. Cardiovasc Interv Radiol. 2007;30(5):936–42.CrossRef

95.

Zagoria RJ, Pettus JA, Rogers M, Werle DM, Childs D, Leyendecker JR. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology. 2011;77(6):1393–7.PubMedCrossRef

96.

Veltri A, Gazzera C, Busso M, Solitro F, Piccoli GB, Andreetto B, et al. T1a as the sole selection criterion for RFA of renal masses: randomized controlled trials versus surgery should not be postponed. Cardiovasc Interv Radiol. 2014;37(5):1292–8.CrossRef

97.

Kim SD, Yoon SG, Sung GT. Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol. 2012;13(5):625–33.PubMedPubMedCentralCrossRef

98.

Atwell TD, Schmit GD, Boorjian SA, Mandrekar J, Kurup AN, Weisbrod AJ, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol. 2013;200(2):461–6.PubMedCrossRef

99.

Zargar H, Atwell TD, Cadeddu JA, de la Rosette JJ, Janetschek G, Kaouk JH, et al. Cryoablation for small renal masses: selection criteria, complications, and functional and oncologic results. Eur Urol. 2016;69(1):116–28.PubMedCrossRef

100.

Zorn KC, Orvieto MA, Mikhail AA, Lyon MB, Gerber GS, Steinberg GD, et al. Case report: radiofrequency ablation-induced renal-pelvic obstruction resulting in nephrectomy. J Endourol. 2007;21(9):1059–63.PubMedCrossRef

101.

Park BK, Kim CK. Complications of image-guided radiofrequency ablation of renal cell carcinoma: causes, imaging features and prevention methods. Eur Radiol. 2009;19(9):2180–90.PubMedCrossRef

102.

Froghi S, Ahmed K, Khan MS, Dasgupta P, Challacombe B. Evaluation of robotic and laparoscopic partial nephrectomy for small renal tumours (T1a). BJU Int. 2013;112(4):E322–33.PubMedCrossRef

103.

Bhan SN, Pautler SE, Shayegan B, Voss MD, Goeree RA, You JJ. Active surveillance, radiofrequency ablation, or cryoablation for the nonsurgical management of a small renal mass: a cost-utility analysis. Ann Surg Oncol. 2013;20(11):3675–84.PubMedCrossRef

Titel: CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma
verfasst von: Miltiadis E. Krokidis
Franco Orsi
Konstantinos Katsanos
Thomas Helmberger
Andy Adam
Publikationsdatum: 16.12.2016
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 2/2017
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-016-1531-y

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma

Excerpt

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Proximal Occlusion of Medium-Sized Vessels with the Penumbra Occlusion Device: A Study of Safety and Efficacy

Risk Prediction of New Adjacent Vertebral Fractures After PVP for Patients with Vertebral Compression Fractures: Development of a Prediction Model

Pulmonary Arteriovenous Malformations Embolized Using a Micro Vascular Plug System: Technical Note on a Preliminary Experience

Endovascular Management of Recurrent Spontaneous Hemarthrosis After Arthroplasty

Balloon-Occluded Retrograde Transvenous Obliteration of a Gastric Vascular Malformation: An Innovative Approach to Treatment of a Rare Condition

Direct Injection of Blood Products Versus Gelatin Sponge as a Technique for Local Hemostasis

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie